CClinicalTrials.gg
CompletedNCT05818280VAR-24hFRUpdated Jun 19, 2025

Relationship Between 24-hour Blood Pressure Variability and FRagility in the Elderly Patient

An observational study in Hypertension, sponsored by Pr. Nicolas GIRERD. Completed at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Pr. Nicolas GIRERD · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Ages
75 Years and older
Sex
All
01

Study summary

In the 2016's Haute Autorité de Santé (HAS) recommendations (Haute Autorité de Santé. Management of arterial hypertension in adults. Saint-Denis La Plaine: HAS; 2016.) concerning the management of arterial hypertension in adults, the Ambulatory Blood Pressure Measurement (ABPM) is described as a diagnostic tool for hypertension as well as a tool useful for checking blood pressure (BP) control in treated patients.

It is also stipulated that ABPM can provide additional information such as the exploration of significant blood pressure variability.

The 2014's ESH recommendations (ESH practical guidelines for ambulatory blood pressure monitoring, 2014) concerning ABPM indicate that variability of BP over 24 hours can be considered as a research parameter.

Blood Pressure Variability could be a better predictor of organ damage related to hypertension than blood pressure measured in consultation.

Furthermore, BP measurement over 24 hours has been demonstrated as a more sensitive risk factor for cardiovascular events such as stroke or ischemic coronary events.

It is specified in the 2018 ESH/ESC guidelines on the management of hypertension (Mancia G, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. 2018) that an additional number of ABPM parameters may have prognostic value such as 24-hour variability even if there is no indication yet of its evaluation in clinical routine.

The variability of blood pressure is associated with an increased risk of cardiovascular events, in particular stroke and coronary events in young and hypertensive patients, regardless of their cardiovascular risk factors, mean value of their systolic BP measured in ABPM or during consultation follow-up as shown by Rothwell PM et al. (Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. mars 2010;375(9718):895-905) and Mehlum MH et al. (Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 21 juin 2018;39(24):2243-51.)

Studies also show that BP variability in elderly hypertensive patients is an independent risk factor for cardiovascular events (Eto M et al. Impact of Blood Pressure Variability on Cardiovascular Events in Elderly Patients with Hypertension. Hypertens Res. 2005;28(1):1-7.) and that BP variability would be greater in the elderly patient (Magdás A et al. Ambulatory monitoring derived blood pressure variability and cardiovascular risk factors in elderly hypertensive patients. Biomed Mater Eng. 2014;24(6):2563-9)

Finally, a link between frailty and blood pressure variability is demonstrated by Rouch L et al. (Visit-to-Visit Blood Pressure Variability and Incident Frailty in Older Adults. Le Couteur D, éditeur. J Gerontol Ser A. 13 juill 2021;76(8):1369-75.) However, BP variability, measured in this study by blood pressure variation between clinical visits, does not assess overnight variability. Another limitation in the evaluation of frailty is the exclusion of patients with an MMSE \< 24.

Hussain SM et al. (Variation in Mean Arterial Pressure Increases Falls Risk in Elderly Physically Frail and Prefrail Individuals Treated With Antihypertensive Medication. Hypertension. sept 2022;79(9):2051-61.) also show that BP variability measured by ABPM would increase the risk of serious falls in frail or pre-frail elderly subjects taking antihypertensive treatment.

The objective of this study is therefore to evaluate the link between blood pressure variability on 24-hour recordings measured by the standard deviation and the coefficient of variation, according to the frailty status in patients aged over 75 with hypertension, treated or not with antihypertensive molecules.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Frail patient
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 49 is below the median of 210 across 1,359 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Pr. Nicolas GIRERD is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over 75 years old, admitted for consultation or day hospitalisation in the Geriatric Service of the CHRU, living at home, with treated or untreated hypertension with clinical indication for an ABPM and Clinical indication for a frailty measurement

Inclusion criteria

  • Patients over 75 years old, men and women,
  • Patients admitted for consultation or day hospitalisation to the Geriatric Service of the CHRU, living at home, with treated or untreated hypertension with :
  • Clinical indication for an ABPM
  • Clinical indication for a frailty measurement

Exclusion criteria

Exclusion Criteria:

  • Opposition to the use of data
  • Inability to perform ABPM
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Standard deviation of 24 hours Systolic Arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

Secondary outcomes

  1. Coefficient of variation of 24 hours systolic Arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  2. Standard deviation of 24 hours Diastolic Arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  3. Standard deviation of 24 hours Pulse arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  4. Standard deviation of 24 hours Mean arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  5. Coefficient of variation of 24 hours Diastolic Arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  6. Coefficient of variation of 24 hours Pulse arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

  7. Coefficient of variation of 24 hours Mean arterial blood pressure

    Assessed on 24-hour Arterial Blood Pressure Measurement (ABPM)

    Time frame: From inclusion until 24 hours

07

Study locations

1 site
  • CHRU de NANCY
    Vandœuvre-lès-Nancy, 54500, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05818280
Lead sponsor
Pr. Nicolas GIRERD
Responsible party
Pr. Nicolas GIRERD (Study chair, Central Hospital, Nancy, France) — Sponsor-investigator
First posted
Apr 18, 2023
Start date
Jan 12, 2023
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Last update
Jun 19, 2025

Study contacts

Nicolas GIRERD, MD-PhD
study chair · CHRU de NANCY

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion